Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Other solid neoplasm 1

Conditions

Advanced Solid Tumors 432Advanced Solid Tumor 352Solid Tumor 305Solid Tumors 246Mesothelioma 115Solid Tumor, Adult 76Mesothelioma, Malignant 72Carcinoma, Non-Small-Cell Lung 66Ovarian Neoplasms 47Melanoma 42Carcinoma, Renal Cell 37Colorectal Neoplasms 34Advanced or Metastatic Solid Tumors 32Uterine Cervical Neoplasms 31Stomach Neoplasms 31Solid Tumours 31Esophageal Neoplasms 30Neoplasms 27Pancreatic Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Advanced Malignant Solid Tumors 25Triple Negative Breast Neoplasms 24Lung Neoplasms 24Small Cell Lung Carcinoma 23Advanced Solid Tumours 23Sarcoma 21Neoplasm Metastasis 21Advanced Malignant Solid Tumor 21Locally Advanced or Metastatic Solid Tumors 20

Interventions

1-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Platinum-resistant Recurrent Ovarian Cancer × Other solid neoplasm × Clear all
NCT06687070 2025-02-26

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Ascentage Pharma Group Inc.

Phase 1 Recruiting
50 enrolled
GynecologicOther solid neoplasm

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡